Literature DB >> 22998806

3 cases of primary intracranial hemorrhage associated with "Molly", a purified form of 3,4-methylenedioxymethamphetamine (MDMA).

D Ethan Kahn1, Nicholas Ferraro, Ronald J Benveniste.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA, or "Ecstasy" in tablet form) is a powerful sympathomimetic drug that is commonly perceived as safer than other stimulants such as methamphetamine or cocaine. "Molly" is a purified form of MDMA that is perceived by users as being even safer, as it is free of adulterants such as methamphetamine. Previously, all reports of intracranial hemorrhages in MDMA abusers were associated with coingestion of other sympathomimetic drugs, or with pre-existing cerebrovascular lesions. We describe a series of three young, otherwise healthy patients with various types of intracranial hemorrhages associated with "Molly" ingestion. All three patients underwent extensive workup including catheter angiography that did not demonstrate aneurysm, arteriovenous malformation, or vasculitis. We suggest that even the purified form of MDMA can cause serious intracranial hemorrhagic complications and should not be thought of as a safe recreational drug.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22998806     DOI: 10.1016/j.jns.2012.08.031

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  11 in total

Review 1.  The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.

Authors:  Philip Kamilar-Britt; Gillinder Bedi
Journal:  Neurosci Biobehav Rev       Date:  2015-09-25       Impact factor: 8.989

2.  An examination of sociodemographic correlates of ecstasy use among high school seniors in the United States.

Authors:  Joseph J Palamar; Dimitra Kamboukos
Journal:  Subst Use Misuse       Date:  2014-06-23       Impact factor: 2.164

3.  An Examination of the Most Recent Episode of Molly Use among College Students.

Authors:  Amy L Stamates; Ashley N Linden-Carmichael; Brynn E Sheehan; Peter D Preonas; Cathy Lau-Barraco
Journal:  J Drug Issues       Date:  2017-01-10

4.  Controversies and evolving new mechanisms in subarachnoid hemorrhage.

Authors:  Sheng Chen; Hua Feng; Prativa Sherchan; Damon Klebe; Gang Zhao; Xiaochuan Sun; Jianmin Zhang; Jiping Tang; John H Zhang
Journal:  Prog Neurobiol       Date:  2013-09-25       Impact factor: 11.685

Review 5.  Cerebrovascular and cardiovascular diseases caused by drugs of abuse.

Authors:  Yuichi Akasaki; Mitsuru Ohishi
Journal:  Hypertens Res       Date:  2019-12-05       Impact factor: 3.872

6.  Posterior spinal artery aneurysm rupture after 'Ecstasy' abuse.

Authors:  Jeremiah Johnson; Shnehal Patel; Efrat Saraf-Lavi; Mohammad Ali Aziz-Sultan; Dileep R Yavagal
Journal:  BMJ Case Rep       Date:  2014-07-03

7.  Molly users versus nonusers in a sample of college alcohol drinkers: Differences in substance-related harms and sensation seeking.

Authors:  Ashley N Linden-Carmichael; Amy L Stamates; Brynn E Sheehan; Cathy Lau-Barraco
Journal:  Subst Abus       Date:  2016-01-28       Impact factor: 3.716

Review 8.  A Mechanistic and Pathophysiological Approach for Stroke Associated with Drugs of Abuse.

Authors:  Aristides Tsatsakis; Anca Oana Docea; Daniela Calina; Konstantinos Tsarouhas; Laura-Maria Zamfira; Radu Mitrut; Javad Sharifi-Rad; Leda Kovatsi; Vasileios Siokas; Efthimios Dardiotis; Nikolaos Drakoulis; George Lazopoulos; Christina Tsitsimpikou; Panayiotis Mitsias; Monica Neagu
Journal:  J Clin Med       Date:  2019-08-23       Impact factor: 4.241

Review 9.  3,4-methylenedioxymethamphetamine (MDMA): current perspectives.

Authors:  Jerrold S Meyer
Journal:  Subst Abuse Rehabil       Date:  2013-11-21

10.  Rapidly reversible multiorgan failure after ingestion of "Molly" (pure 3,4-methylenedioxymethamphetamine): a case report.

Authors:  Trupti Vakde; Manuel Diaz; Kalpana Uday; Richard Duncalf
Journal:  J Med Case Rep       Date:  2014-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.